Top-News

Navidea Biopharmaceuticals News

Aktie
WKN:  A1JSBX ISIN:  US63937X1037
Keine aktuellen Kursdaten verfügbar
Handeln Depot/Watchlist
Dieses Wertpapier ist nicht mehr handelbar.
Aktienanzahl *
163,62 Mio.
Marktkapitalisierung *
-
Streubesitz
-
Index-Zugehörigkeit
-
IR-Website
zur Website
*Stand: 10.09.2018

Navidea Biopharmaceuticals News

12.08.20 - PR Newswire
Thinking about buying stock in Navidea Biopharmaceuticals, CleanSpark Inc, Aerpio Pharmaceuticals, Hertz Global Holdings, or Walt Disney?
Thinking about buying stock in Navidea Biopharmaceuticals, CleanSpark Inc, Aerpio Pharmaceuticals, Hertz Global Holdings, or Walt Disney? PR Newswire
22.05.20 - PR Newswire
Thinking about buying stock in Xeris Pharmaceuticals, Aquestive Therapeutics, Navidea Biopharmaceuticals, Sundial Growers, or Hexo Corp?
Thinking about buying stock in Xeris Pharmaceuticals, Aquestive Therapeutics, Navidea Biopharmaceuticals, Sundial Growers, or Hexo Corp? PR Newswire
22.05.20 - PR Newswire
Thinking about buying stock in Navidea Biopharmaceuticals, Aurora Cannabis, Under Armour, Onconova Therapeutics, or BJs Wholesale Club?
Thinking about buying stock in Navidea Biopharmaceuticals, Aurora Cannabis, Under Armour, Onconova Therapeutics, or BJs Wholesale Club? PR Newswire
29.10.19 - PR Newswire
Thinking about buying stock in Cronos Group, Navidea Biopharmaceuticals, PG&E, Pfizer, or Top Ships?
Thinking about buying stock in Cronos Group, Navidea Biopharmaceuticals, PG&E, Pfizer, or Top Ships? PR Newswire
11.04.14 - PR Newswire
Navidea Pharmaceuticals Inc. Analyst Report: Long Term Market Potential of Lymphoseek does not Justify Current Valuation by BrokerBank Securities, Inc.
Navidea Pharmaceuticals Inc. Analyst Report: Long Term Market Potential of Lymphoseek does not Justify Current Valuation by BrokerBank Securities, Inc. PR Newswire
13.08.13 - PR Newswire
Robbins Arroyo LLP Is Investigating the Directors and Officers of Navidea Biopharmaceuticals, Inc.
Robbins Arroyo LLP Is Investigating the Directors and Officers of Navidea Biopharmaceuticals, Inc. PR Newswire
03.06.13 - PR Newswire
SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Possible Breaches of Fiduciary Duty by the Board of Directors of Navidea Biopharmaceuticals, Inc.
SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Possible Breaches of Fiduciary Duty by the Board of Directors of Navidea ...
11.09.12 - Aktiencheck
Navidea Biopharmaceuticals-Aktie: "buy" - Ladenburg Thalmann
Die Analysten von Ladenburg Thalmann vergeben für die Aktie von Navidea Biopharmaceuticals nach wie vor das Rating Votum "buy". Das Kursziel werde von 6,25 USD auf 7,50 ...
11.09.12 - Aktiencheck
Navidea Biopharmaceuticals-Aktie: Kursziel gesenkt - Rodman & Renshaw
Die Analysten von Rodman & Renshaw bewerten die Aktie von Navidea Biopharmaceuticals weiterhin mit dem Votum "market outperform". Das Kursziel werde von 7,00 USD auf ...
22.08.12 - Aktiencheck
Navidea Biopharmaceuticals-Aktie: "buy" - ThinkEquity Partners
Spencer Nam und Mary Nielson, Analysten von ThinkEquity Partners, stufen die Aktie von Navidea Biopharmaceuticals weiterhin mit "buy" ein. Das Kursziel werde bei 7 USD ...
31.07.12 - PR Newswire
Alseres Pharmaceuticals, Inc. Reports License of Altropane® Worldwide Rights to Navidea Biopharmaceuticals, Inc.
Alseres Pharmaceuticals, Inc. Reports License of Altropane® Worldwide Rights to Navidea Biopharmaceuticals, Inc. Conference Call to be Held Wednesday, August 1, 2012 at ...
23.07.12 - Aktiencheck
Navidea Biopharmaceuticals-Aktie: vielversprechende Pipeline - Hot Stocks Investor
Die Experten vom "Hot Stocks Investor" halten bei der Aktie von Navidea Biopharmaceuticals ein Kurspotenzial von 50% für möglich. Aktuell stünden drei viel versprechende ...

Newssuche

Videos

newspaper
17.05.24 -4,89%
Technical Trading: Gold Long-​Chance
Gold Long Typ: Turbo Open End WKN: VD1G7Y Hebel: 10 Laufzeit: OpenEnd Einstieg: Market ... Mehr »